Science Immunology

Supplementary Materials

The PDF file includes:

  • Fig. S1. Validation of the LAG3NC conditional knock-in mouse.
  • Fig. S2. Tumor growth and analysis of TILs isolated from Lag3NC.L/L and Lag3NC.L/L CD4Cre mice.
  • Fig. S3. Restriction of LAG3NC to T cells affects anti-PD1–mediated tumor regression.
  • Fig. S4. Single-cell RNA-seq analysis of MC38 tumor-infiltrating T cells isolated from Lag3NC.L/L and Lag3NC.L/L CD4Cre mice.
  • Fig. S5. Transcriptomic analysis of LAG3NC conventional CD4+ T cells in the context of PD1 blockade.
  • Fig. S6. Transcriptomic analysis of LAG3NC regulatory CD4+ T cells in the context of PD1 blockade.
  • Fig. S7. Transcriptomic analysis of LAG3NC CD8+ T cells in the context of PD1 blockade.
  • Fig. S8. Tumor growth of Lag3NC.L/L ThPOKCreERT2 mice and analysis of tumor-infiltrating conventional CD4+ T cells isolated from Lag3NC.L/L and Lag3NC.L/L CD4Cre mice in the context of PD1 blockade.
  • Fig. S9. Tumor growth of Lag3NC.L/L Foxp3CreERT2 mice and analysis of tumor-infiltrating regulatory CD4+ T cells isolated from Lag3NC.L/L and Lag3NC.L/L CD4Cre mice in the context of PD1 blockade.
  • Fig. S10. Tumor growth of Lag3NC.L/L E8ICre.GFP mice and analysis of tumor-infiltrating CD8+ T cells isolated from Lag3NC.L/L, Lag3NC.L/L CD4Cre, and Lag3NC.L/L E8ICre.GFP mice in the context of PD1 blockade.
  • Fig. S11. Adoptive transfer of CD8+ pmel into B16-gp100 tumor-bearing Lag3NC.L/L and Lag3NC.L/L CD4Cre mice.
  • Fig. S12. Inhibition of ADAM10-mediated LAG3 shedding in vitro and in vivo.
  • Fig. S13. LAG3 and ADAM10 expression on PBL and TIL isolated from patients with metastatic melanoma (cohort A).
  • Fig. S14. LAG3 and ADAM10 expression on PBL isolated from patients with advanced skin cancer (cohort B).
  • Fig. S15. LAG3 and ADAM10 expression on PBL and TIL isolated from patients with HNSCC (cohort C).
  • Fig. S16. LAG3 and ADAM10 expression on PBL isolated from treatment-naïve patients with HNSCC (cohort D).

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Fold change and corrected P value for BD between random and sample conditions.
  • Table S2 (Microsoft Excel format). Cohort A clinical information of patient with metastatic melanoma.
  • Table S3 (Microsoft Excel format). Patient cohort B clinical information.
  • Table S4 (Microsoft Excel format). Cohort C clinical information of patient with HNSCC patient.
  • Table S5 (Microsoft Excel format). Cohort D clinical information of treatment-naïve patient with HNSCC.
  • Table S6 (Microsoft Excel format). Raw data file.

Files in this Data Supplement: